Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,943
  • Shares Outstanding, K 58,792
  • Annual Sales, $ 11,000 K
  • Annual Income, $ -69,780 K
  • EBIT $ -66 M
  • EBITDA $ -65 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.19
  • Most Recent Earnings $-0.27 on 11/13/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 377.91% (-3.49%)
  • Historical Volatility 133.16%
  • IV Percentile 46%
  • IV Rank 27.16%
  • IV High 1,150.98% on 08/08/25
  • IV Low 89.72% on 01/14/26
  • Expected Move (DTE 33) 0.3230 (100.25%)
  • Put/Call Vol Ratio 10.00
  • Today's Volume 22
  • Volume Avg (30-Day) 171
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 13,797
  • Open Int (30-Day) 13,331
  • Expected Range 0.0000 to 0.6452

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2926 +10.12%
on 01/13/26
0.8399 -61.64%
on 12/26/25
-0.4379 (-57.61%)
since 12/16/25
3-Month
0.2926 +10.12%
on 01/13/26
1.4300 -77.47%
on 11/19/25
-0.4141 (-56.24%)
since 10/16/25
52-Week
0.2400 +34.25%
on 03/04/25
1.4300 -77.47%
on 11/19/25
-0.1637 (-33.69%)
since 01/16/25

Most Recent Stories

More News
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026. BioAtla...

BCAB : 0.3222 (+0.81%)
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with...

BCAB : 0.3222 (+0.81%)
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval...

BCAB : 0.3222 (+0.81%)
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved...

BCAB : 0.3222 (+0.81%)
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 0.3222 (+0.81%)
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 0.3222 (+0.81%)
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response...

BCAB : 0.3222 (+0.81%)
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 0.3222 (+0.81%)
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated...

BCAB : 0.3222 (+0.81%)
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 0.3222 (+0.81%)

Business Summary

BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.3971
2nd Resistance Point 0.3813
1st Resistance Point 0.3517
Last Price 0.3222
1st Support Level 0.3063
2nd Support Level 0.2905
3rd Support Level 0.2609

See More

52-Week High 1.4300
Fibonacci 61.8% 0.9754
Fibonacci 50% 0.8350
Fibonacci 38.2% 0.6946
Last Price 0.3222
52-Week Low 0.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar